CoChat

Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective

ARIOGLU, ELIF, ANDEWELT, ALEXA, DIABO, CRYSTAL, BELL, MELISSA, TAYLOR, SIMEON I., GORDEN, PHILLIP · 2002 · Medicine

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Abstract

Introduction The type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor. It is representative of a class of disease in which an autoantibody is produced against a cell surface receptor (9,79). Graves disease, caused by autoantibodies to the thyroid stimulating hormone receptor, and myasthenia gravis, caused by autoantibodies to the acetylcholine receptor at the myoneural junction, are typical of these diseases (30). Other rare syndromes include gonadal deficiencies and iron deficiencies (46,61). The exact prevalence of type B insulin resistance syndrome is not known; however, it is quite rare. There have been no population-based studies to answer the question of disease prevalence. Autoantibodies to the insulin receptor were first identified in middle-aged women with other autoimmune diseases (26,36). Subsequently, it was recognized that the disease also affects males and younger patients (4,15,24,53). The disease causes a spectrum of abnormalities in glucose homeostasis, ranging from extreme insulin resistance (30) to fasting hypoglycemia (30,69), and in some other cases a change from extreme insulin resistance to intractable hypoglycemia (1,67,69). In addition, the abnormalities in glucose homeostasis may remit in association with the disappearance of the antibody to the insulin receptor. While all these phenomena have been observed and reported over the years, little is known about the long-term prognosis of the patients. Furthermore, various treatment modalities have been employed to treat the syndrome without adequate appreciation of the disease course in the long run. In this paper we review the natural history of type B insulin resistance syndrome using clinical data from 24 patients followed for up to 28 years. Methods Patients and objective Twenty-four patients with the diagnosis of type B insulin resistance syndrome were admitted to the Clinical Center of the National Institutes of Health (NIH), Bethesda, Maryland, between January 1973 and December 2000. The data gathered on these patients were retrospectively evaluated to draw conclusions about the clinical outcomes. Criteria for inclusion Patients were required to have demonstrable autoantibodies against the insulin receptor in association with a clinical abnormality of glucose homeostasis, that is, hyperglycemia or hypoglycemia. Data collection Because of the wide geographic origins of these patients, it was not possible to follow each patient at the Clinical Center for the duration of time reported; therefore, we have supplemented our information by correspondence and telephone. Each patient underwent a detailed history and physical examination and in most cases they were followed for months or years at the Clinical Center. As retrospective information on each case was compiled, specific attention was given to delineate the onset of the syndrome, associated features, therapeutic interventions, outcome of therapy and metabolic responses (resolution of glucose abnormalities) over the course of follow-up, current status, and mortality. In addition, a similar approach was taken to derive complete follow-up information on cases reported in the literature wherever possible. Laboratory tests All patients underwent a battery of routine hematologic, immunologic, and biochemical tests on their initial examination, and on multiple subsequent time points. Most patients underwent a standard oral glucose tolerance test, and patients presenting with hypoglycemia underwent a diagnostic fast at least at the time of initial presentation. Each patient was proven to have an insulin receptor autoantibody by assays that measured either inhibition of insulin binding or blocking the biologic activity of insulin (30). A newer method detected antireceptor antibody by measuring immunoprecipitation of recombinant human insulin receptors. This method, developed in 1997, has improved specificity and sensitivity (Figure 1).Fig. 1: A newer method detected anti-insulin receptor antibody by measuring immunoprecipitation of recombinant human insulin receptors. Cos 7 cells were transfected with recombinant human insulin receptors using LipofectAMINE Plus according to manufacturer’s instructions (Life Technologies, Gaithersburg, MD). The cells were solubilized for 30 minutes on ice and insoluble debris removed by centrifugation (14,000 G for 20 minutes) at 4 °C. To test for the presence of the antireceptor antibody in the patients’ sera, 150 μL of extract was incubated with 2 μL of patient serum overnight at 4 °C. The antibody bound receptors were precipitated with peroxidase-affinity pure Fab′ 2 fragment goat antirabbit IgG −Fc fragment specific antibody (Jackson Immunological Research, West Grove, PA) and blotted with anti-insulin receptor β-subunit rabbit polyclonal antibody (C19) (Santa Cruz, CA). Nine samples were screened on the gel shown. Samples on Lane 1 and 8 are positive. Samples on lane 8 and 9 belong to the same patient at 2 d

Overview

Integrity signals

Registry

Crossref · 10.1097/00005792-200203000-00001

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 84 references

Research works printed but not linked: 9

  1. Auclair, 1999, J Clin Endocrinol Metab, 84, 3197
  2. Dozio, 1998, J Clin Endocrinol Metab, 83, 643
  3. Gill, 1994, J Reprod Med, 39, 126
  4. Jennette, 1982, Arch Pathol Lab Med, 106, 218
  5. Kramer, 1998, J Rheumatol, 25, 816
  6. O’Brien, 1994, J Clin Endocrinol Metab, 79, 290
  7. Sluss, 1992, J Clin Endocrinol Metab, 74, 1242
  8. Tardella, 1983, J Clin Lab Immunol, 12, 159
  9. Varga, 1990, J Rheumatol, 17, 1226

Cited by

See all 223

Metadata

Authors
ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P.
Affiliations
National Institutes of Health (US)
Venue
Medicine
Published
2002-03
Volume
81
Issue
2
Pages
87-100
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2087454504
Cited by
223
References
84
Citations by year
2026: 7 · 2025: 9 · 2024: 10 · 2023: 16 · 2022: 12 · 2021: 10 · 2020: 16 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 15 · 2015: 11 · 2014: 10 · 2013: 9 · 2012: 10
FWCI
2.27
Type
journal article
Language
en
Open access
closed
Locations
  • Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
Keywords
type B insulin resistance syndrome, insulin receptor antibodies, insulin resistance, hypoglycemia, hyperglycemia, glucose homeostasis, long-term prognosis, natural history (disease), remission, treatment outcomes, autoimmune disease, clinical course, immunosuppressive therapy, Graves' disease, myasthenia gravis
MeSH terms
Acanthosis Nigricans, Adolescent, Adrenal Cortex Hormones, Adult, Aged, Autoimmune Diseases, Body Composition, Cause of Death, Child, Female, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Immunosuppressive Agents, Insulin Resistance, Male, Middle Aged, Plasmapheresis, Receptor, Insulin, Retrospective Studies, Syndrome, United States, Hyperandrogenism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective. https://app.cochat.ai/papers/10.1097/00005792-200203000-00001
The paper
ARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002). Clinical Course of the Syndrome of Autoantibodies to the Insulin Receptor (Type B Insulin Resistance): A 28-Year Perspective. Medicine. https://doi.org/10.1097/00005792-200203000-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.